Your browser doesn't support javascript.
Predictive risk factors for hospitalization and response to colchicine in patients with COVID-19.
Tardif, Jean-Claude; Cossette, Mariève; Guertin, Marie-Claude; Bouabdallaoui, Nadia; Dubé, Marie-Pierre; Boivin, Guy.
  • Tardif JC; Montreal Heart Institute and Université de Montréal, Montreal, QC, Canada.
  • Cossette M; Montreal Health Innovations Coordinating Center (MHICC), Montreal, QC, Canada.
  • Guertin MC; Montreal Health Innovations Coordinating Center (MHICC), Montreal, QC, Canada.
  • Bouabdallaoui N; Montreal Heart Institute and Université de Montréal, Montreal, QC, Canada.
  • Dubé MP; Montreal Heart Institute and Université de Montréal, Montreal, QC, Canada.
  • Boivin G; Research Center in Infectious Diseases, CHU de Québec and Université Laval, Quebec City, QC, Canada. Electronic address: Guy.Boivin@crchudequebec.ulaval.ca.
Int J Infect Dis ; 116: 387-390, 2022 Mar.
Article in English | MEDLINE | ID: covidwho-1620729
ABSTRACT

OBJECTIVE:

A predictive model for hospitalization due to COVID-19 or death was developed in the placebo group (N=2,084) from a large clinical trial of colchicine in COVID-19 patients (N = 4,159).

RESULTS:

The 7 variables retained in the predictive model were age, gender, body-mass index, history of respiratory disease, use of diabetes drugs, use of anticoagulants, and use of oral steroids at the time of randomization. An optimal threshold value identified from the predictive model was used to classify high-risk patients (those with a predicted probability above the optimal threshold) and low-risk patients (those with a predicted probability below the optimal threshold). The number needed to treat to prevent 1 hospitalization or death with colchicine treatment decreased from 71 in the whole study population (N = 4,159) to 29 in the high-risk subgroup (N=1,692).

CONCLUSION:

This model could serve to identify high-risk subjects who will particularly benefit from early colchicine therapy.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 Drug Treatment Type of study: Experimental Studies / Prognostic study / Randomized controlled trials Limits: Humans Language: English Journal: Int J Infect Dis Journal subject: Communicable Diseases Year: 2022 Document Type: Article Affiliation country: J.ijid.2022.01.020

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 Drug Treatment Type of study: Experimental Studies / Prognostic study / Randomized controlled trials Limits: Humans Language: English Journal: Int J Infect Dis Journal subject: Communicable Diseases Year: 2022 Document Type: Article Affiliation country: J.ijid.2022.01.020